WO2021220288A1 - Fabric mask coated wtih hcq, azithromycin - Google Patents
Fabric mask coated wtih hcq, azithromycin Download PDFInfo
- Publication number
- WO2021220288A1 WO2021220288A1 PCT/IN2020/050812 IN2020050812W WO2021220288A1 WO 2021220288 A1 WO2021220288 A1 WO 2021220288A1 IN 2020050812 W IN2020050812 W IN 2020050812W WO 2021220288 A1 WO2021220288 A1 WO 2021220288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fabric
- mask
- ambient air
- protective gear
- drags
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
- A41D13/1192—Protective face masks, e.g. for surgical use, or for use in foul atmospheres with antimicrobial agent
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
- A62B18/00—Breathing masks or helmets, e.g. affording protection against chemical agents or for use at high altitudes or incorporating a pump or compressor for reducing the inhalation effort
- A62B18/02—Masks
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
- A62B23/00—Filters for breathing-protection purposes
- A62B23/02—Filters for breathing-protection purposes for respirators
-
- D—TEXTILES; PAPER
- D21—PAPER-MAKING; PRODUCTION OF CELLULOSE
- D21H—PULP COMPOSITIONS; PREPARATION THEREOF NOT COVERED BY SUBCLASSES D21C OR D21D; IMPREGNATING OR COATING OF PAPER; TREATMENT OF FINISHED PAPER NOT COVERED BY CLASS B31 OR SUBCLASS D21G; PAPER NOT OTHERWISE PROVIDED FOR
- D21H21/00—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties
- D21H21/14—Non-fibrous material added to the pulp, characterised by its function, form or properties; Paper-impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
- D21H21/36—Biocidal agents, e.g. fungicidal, bactericidal, insecticidal agents
Definitions
- the technical field of invention relates to the field of medical personal protection equipments. Still further the invention deals with cotton fabric material coated approved drags (hydroxychloroquine, azithromycin) at non-toxic, health and safety compliant sub-lethal and micro-molar doses. Further, the invention relates to practicable tailor-made solution to assist the public amongst other viral pandemics suppressive measures. Furthermore, the invention is to provide personal protection gear to alleviate the distress of vast majority of economically challenged people in India who are finding it increasingly difficult to adhere to strict social distancing, and those of whom are inevitably compelled to make essential trips, either wear cloth mask / face covering unfit for personal protection against the contagions (e.g. virus) or cannot afford high end nanofibre fitted filters.
- contagions e.g. virus
- the two drugs can be tactically, and safely held in proportionately several folds lower than those of recommended oral dosages (that are normally based on body weight to combat microbes internally at higher levels) and thus our goal is to challenge the viruses at sub- lethal dosage for achieving the antiviral effects.
- the coated substrate was a 100% cotton fabric (144 gm-2) used for mask-making (supplied by a textile factory located in Tirupur, Tamil Nadu, India).
- the methods adapted and modified from standard operating procedures broadly developed for testingmedicalfabric coating with antimicrobials.
- the aforementioned drags prepared at sub-lethal millimolar concentrations coated onto sample fabric pre-sterilised (e.g. autoclaved, UV/gamma irradiated) and dipped in the relevant dilutions of the drugs. Aliquots of plaque or viroid colony (titre) suspensionswerechallenged on the cotton fabric samples (circular bits) of our invention.
- the percentage ratio between the average numbers of surviving plaques before (A) and after (B) contact with the coated fabrics determined the antiviral efficiency of the drugs and viral morbidity achieved in our invention and calculated by (B) -(A) /(B)xl00.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Business, Economics & Management (AREA)
- Emergency Management (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Textile Engineering (AREA)
- Pest Control & Pesticides (AREA)
- Respiratory Apparatuses And Protective Means (AREA)
Abstract
A fabric personal protection equipment (PPE - mask, fabrics) offering general viral suppression with approved drugs in sublethal, non-toxic, health and safety compliant proportion is provided. The lower levels of titres of common viruses encountered in ambient air are reduced by drug-assisted coating together with a bio-safe contagion binding agent added on fabric matrix by 80-100%. This drug-assisted fabric matrix aims at improvisation such as fabric cotton mask and other personal protection wear through industrial upscaling of the fabric PPE manufacturing process. This protects individuals from breathing the contagion circulation in ambient air. It helps alleviate the distress of economically challenged people to balance their essential outings in open air and adhering to social distancing requirements in pandemics, and is a cheaper, effective PPE wear fabrics for healthcare use.
Description
FABRIC MASK COATED WTIH HCQ, AZITHROMYCIN
FIELD OF INVENTION: -
The technical field of invention relates to the field of medical personal protection equipments. Still further the invention deals with cotton fabric material coated approved drags (hydroxychloroquine, azithromycin) at non-toxic, health and safety compliant sub-lethal and micro-molar doses. Further, the invention relates to practicable tailor-made solution to assist the public amongst other viral pandemics suppressive measures. Furthermore, the invention is to provide personal protection gear to alleviate the distress of vast majority of economically challenged people in India who are finding it increasingly difficult to adhere to strict social distancing, and those of whom are inevitably compelled to make essential trips, either wear cloth mask / face covering unfit for personal protection against the contagions (e.g. virus) or cannot afford high end nanofibre fitted filters.
BACKGROUND OF INVENTION: -
As it is observed that the Novel Corona Virus (Covid - 19) has assumed gargantuan and menacing proportions in the World and has been declared a Pandemic by World Health Organization (WHO) and it has caused enormous destruction to the lives of people across the globe and causing great economic loss and monetary losses to the countries of the World. Every effort is taken up by mankind to provide relief and succour from this killer disease which is dreaded much due to its rapid spreading nature especially by the infected / inflicted persons of the Covid 19 virus to other people.
It is common knowledge that both Indian Council of Medical research (ICMR) and US FDA administrations are supportive of an antimalarial agent hydroxychloroquine and in combination with a commonly prescribed broad spectrum antiviral antibiotic azithromycin
offer effective combating power against coronavirus in high population countries. In the light of the above emerging covid-19 crisis and its management on large populations, the serious global crisis demands not only governmental agencies to act, but urgently require the input from multiple actors in technology and science fields and innovate personal protection/healthcare equipment. In medical emergency circumstances, the oral dosage administration of either hydroxychloroquine or azithromycin is @ milligram/kilogram body weight basis for covid-19 patients or health carers. Insofar as we are concerned and coming from a textile industryor a microbiological persuasion, we intend to target the general public masses themselves, who are often seen using a generic mask as an inadequate personal protection equipment whilst being out in the crowded streets for essentialpurposes. To alleviate the above emerging covid- 19 crisis and contribute practical solutions for its effective management on large populations during the lockdown phase in India, and further to serve as a generic personal protection wear, we, the inventorsintegrated the microbiological sciences and textile industry capacities to test the utility of drug assistance via sub lethal and micro-molar doses of antivirals to be coated on to specially designed cotton face masks that are suitable for hot tropical Indian conditions.
OBJECT OF THE INVENTION: -
It is main object of the present invention to provide a fabric mask that covers the nose and mouth of individuals with two approved drugs of HCQ and Azithromycin in sub-lethal low (micro-molar) levels when supplied in on specially designed masks would offer preventative effects, and reduce the low levels of viroid from ambient air.
It is also a further objective of the invention is based on the prudence that any given viral aerosol dispersion in ambient air will be in very limited load i.e. low titres per cubic metre of the inhaling individual. Thus, the two drugs can be tactically, and safely held in proportionately several folds lower than those of recommended oral dosages (that are normally based on body weight to combat microbes internally at higher levels) and thus our goal is to challenge the viruses at sub- lethal dosage for achieving the antiviral effects.
It is still an additional objective of the proposed invention to produce such lower concentrations of approved drugs coated on the masks that could provide personal protection for individuals from viral incursion from breathing ambient air, as well as the sub-lethal antibiotics adhered on the mask fabric can be regarded as non-toxic, compliant to health and safety of the user.
In a further objective, it is to produce the industrial upscaling of this product (specially designed fabric mask), and using sonochemical methods (ultrasonics) in order to achieve and /or simulate nano-coating of the cotton the material and boost its efficacy against viruses.
DESCRIPTION OF THE INVENTION
The coated substrate was a 100% cotton fabric (144 gm-2) used for mask-making (supplied by a textile factory located in Tirupur, Tamil Nadu, India). The methods adapted and modified from standard operating procedures broadly developed for testingmedicalfabric coating with antimicrobials.
The performance of the FDA (US) and CDSCO (India) approved drags viz., hydroxychloroquine and azithromycincoated fabrics was used for drag assisted viral
extinction capacity of this proposed invention. An agglutinating plant protein was added as a binding agent for the target impinging vims.
For purposes of this invention, the aforementioned drags prepared at sub-lethal millimolar concentrations coated onto sample fabric pre-sterilised (e.g. autoclaved, UV/gamma irradiated) and dipped in the relevant dilutions of the drugs. Aliquots of plaque or viroid colony (titre) suspensionswerechallenged on the cotton fabric samples (circular bits) of our invention.
The percentage ratio between the average numbers of surviving plaques before (A) and after (B) contact with the coated fabrics determined the antiviral efficiency of the drugs and viral morbidity achieved in our invention and calculated by (B) -(A) /(B)xl00.
Claims
Claims
What is claimed is
1) A fabric based protective gear to be worn in the nasal and facial portions of humans whereupon the viroid particulates impinging the individual’s nasal and oral entry points are in real terms be expected at low titres in the ambient air whereupon the claimed protective gear has the approved drags of HCQ ( Hydroxy Chloroquine and Azithromycin)provided at micro-molar levels (i.e. @ sub-lethal levels than that of an oral dosage) as a coating on fabric mask offered a general viral suppression in individuals exposed to ambient air.
2) The fabric based protective gear as claimed in claim 1, wherein, natural biological agglutinating properties of the agent (plant protein) and its innate antiviral potency acts as a booster and the adsorption f bodily fluids (saliva, sweat) onto the fabric matrix acted as added conjugants heightening theantiviral activity of the two approved drags coated on our fabric mask invention, all of which proved advantageous, in that, the lower titres of viruses (encountered in ambient air) are significantly suppressed by 80-100% due to the protein+drags bi-layer coating on the fabric mask.
3) The fabric based protective gear as claimed in claim 1, wherein practicable viral suppressive measures by wearing an antiviral coated (AVC) cloth mask and can provide a simple means to alleviate the distress of economically challenged people in
who are finding it increasingly difficult to follow strict social distancing in the situation of virus (e.g. COVID-19) pandemics.
4)The fabric based protective gear as claimed in claim 1, wherein the drug assisted cloth mask is a scientifically tested option which is economically affordable too than either of the existing practices of cloth (atmospheric particulate pollution) mask and face covering by inadequate fabrics unfit for purpose, or an out of reach, unaffordable expensive choice of high end nanofibre fitted fdters.
5) The fabric based protective gear as claimed in claim 1, wherein sub-lethal concentrations of the two approved drags coated on the masks provide cheaper effective personal protection for individuals from viral incursion from breathing ambient air and also the said sub-lethal antibiotics adhered on the mask fabric can be regarded as nontoxic, compliant to health and safety of the user perspectives.
6) A method of bulk manufacturing (industrial upscaling) of the fabric based mask, achieving enhanced efficacy of the viral inhibitory concentration (VICs) of the drags coated on the fabric using sonochemical methods (ultrasonic nano-coating) of the cotton the material and can be used for making apparels worn by healthcare professionals as Personal Protection Equipment (PPE)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041017816 | 2020-04-27 | ||
IN202041017816 | 2020-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021220288A1 true WO2021220288A1 (en) | 2021-11-04 |
Family
ID=78373377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2020/050812 WO2021220288A1 (en) | 2020-04-27 | 2020-09-23 | Fabric mask coated wtih hcq, azithromycin |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021220288A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120784A (en) * | 1996-02-20 | 2000-09-19 | Viro-Kote, Inc. | Anti-bacterial/anti-viral coatings, coating process and parameters thereof |
US20070026056A1 (en) * | 2000-10-16 | 2007-02-01 | Lectec Corporation | Antiviral patch |
CN109276703A (en) * | 2018-11-06 | 2019-01-29 | 海南森瑞谱生命科学药业股份有限公司 | Antiviral protein of plant complexing agent and preparation method thereof |
US10201198B2 (en) * | 2014-12-23 | 2019-02-12 | Profit Royal Pharmaceutical Limited | Protective masks with coating comprising different electrospun fibers interweaved with each other, formulations forming the same, and method of producing thereof |
-
2020
- 2020-09-23 WO PCT/IN2020/050812 patent/WO2021220288A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6120784A (en) * | 1996-02-20 | 2000-09-19 | Viro-Kote, Inc. | Anti-bacterial/anti-viral coatings, coating process and parameters thereof |
US20070026056A1 (en) * | 2000-10-16 | 2007-02-01 | Lectec Corporation | Antiviral patch |
US10201198B2 (en) * | 2014-12-23 | 2019-02-12 | Profit Royal Pharmaceutical Limited | Protective masks with coating comprising different electrospun fibers interweaved with each other, formulations forming the same, and method of producing thereof |
CN109276703A (en) * | 2018-11-06 | 2019-01-29 | 海南森瑞谱生命科学药业股份有限公司 | Antiviral protein of plant complexing agent and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
THIBAULT FIOLET ET AL.: "Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis", CLINICAL MICROBIOLOGY AND INFECTION, 1 August 2020 (2020-08-01), United Kingdom, Switzerland , XP055743077, ISSN: 1198-743X, DOI: 10.1016/j.cmi.2020.08.022 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Biosafety materials: an emerging new research direction of materials science from the COVID-19 outbreak | |
Elias et al. | Could air filtration reduce COVID-19 severity and spread | |
Fathizadeh et al. | Protection and disinfection policies against SARS-CoV-2 (COVID-19) | |
Vaze et al. | Inactivation of common hospital acquired pathogens on surfaces and in air utilizing engineered water nanostructures (EWNS) based nano-sanitizers | |
AU2020280226A1 (en) | Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes | |
Fan et al. | A theoretical discussion of the possibility and possible mechanisms of using sesame oil for prevention of 2019-nCoV (Wuhan coronavirus) from the perspective of colloid and interface science | |
EP1653983A1 (en) | Non-toxic mucosal disinfectant containing isopropyl alcohol, sesame oil, aloe, and lemon oil | |
WO2021220288A1 (en) | Fabric mask coated wtih hcq, azithromycin | |
WO2013036210A1 (en) | Medical face mask coated with mangosteen shell extracts | |
Agrawal et al. | What all we should know about masks in COVID-19 pandemic | |
Ramaiah et al. | Functionality of nanomaterials and its technological aspects–used in preventing, diagnosing and treating COVID-19 | |
Guha et al. | Effectiveness of facemasks for pediatric populations against submicron-sized aerosols | |
Mulder et al. | COVID-19: Focus on masks and respirators-Implications for oral health-care workers | |
Jagessar | Plant extracts based nanoparticles, potential nanomedicine in fight against COVID-19 | |
CN105902534B (en) | Phenol boheic acid element treats or prevents the application in medicament for treating respiratory system object in preparation | |
US20210138279A1 (en) | Anti-virus filter for facemasks and respirators | |
Mermel | Respiratory protection for healthcare workers caring for COVID-19 patients | |
Branley et al. | Reusing N95 (or P2) masks: current evidence and urgent research questions | |
RU46664U1 (en) | RESPIRATOR | |
Maji et al. | Silver and copper nano particles in mask for Corona Virus-19 protection | |
Li et al. | NIoBReTH: A novel integrative paradigm of protection against SARS-CoV-2 and other airborne pathogens with fewer socioeconomic constraints | |
US20230294026A1 (en) | Anti-viral compositions and method of killing virus | |
SRIDHARAN et al. | A deeper perspective on face masks-a medical aid during severe acute respiratory syndrome (sars) epidemic | |
Harouni et al. | Comparing of Surgical Masks and N95 Masks in Prevention of Influenza: A systematic Review | |
Michailiuk | Personal protection of people during a pandemic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20934103 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20934103 Country of ref document: EP Kind code of ref document: A1 |